# Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

> **NCT01227135** · PHASE2 · UNKNOWN · sponsor: **Lynn McMahon** · enrollment: 66 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** hydroxychloroquine
- **DRUG:** imatinib mesylate
- **GENETIC:** cytogenetic analysis
- **GENETIC:** polymerase chain reaction
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01227135
- **Lead sponsor:** Lynn McMahon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-03
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2011-11-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227135, "Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01227135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*